This review has been published partially in The Cochrane Library (Carbamazepine for Cocaine Dependence). It received the Kenneth Warren Prize given for relevant systematic reviews from developing countries in the last annual Cochrane Meeting (Cape Town, 2000).
Pharmacological treatment of cocaine dependence: a systematic review
Article first published online: 28 JUL 2002
Volume 97, Issue 8, pages 931–949, August 2002
How to Cite
Lima, M. S. d., Soares, B. G. d. O., Reisser, A. A. P. and Farrell, M. (2002), Pharmacological treatment of cocaine dependence: a systematic review. Addiction, 97: 931–949. doi: 10.1046/j.1360-0443.2002.00209.x
- Issue published online: 28 JUL 2002
- Article first published online: 28 JUL 2002
- Cocaine dependence;
- systematic review
Aims Cocaine dependence is a common and serious condition, associated with severe medical, psychological and social problems, including the spread of infectious diseases. This systematic review assesses critically the efficacy of pharmacotherapy for treating cocaine dependence.
Methods The literature search strategy included: electronic searches of Cochrane Library holdings, EMBASE, MEDLINE, PsycLIT, Biological Abstracts and LILACS; scans of reference lists of relevant articles, personal communications, conference abstracts, unpublished trials from the pharmaceutical industry and book chapters on the treatment of cocaine dependence. Randomized controlled trials (RCTs) focusing on the use of antidepressants (ADs), carbamazepine (CBZ), dopamine agonists (DAs) and other drugs used in the treatment of cocaine dependence were included. The reviewers extracted data independently, and relative risks (RR) with 95% confidence interval (CI) were estimated. Qualitative assessments were carried out using a Cochrane validated checklist. Where possible, analysis was carried out according to ‘intention-to-treat’ principles.
Findings The search strategy generated 45 different trials. Most studied drugs were ADs (20 studies), DAs and CBZ. Data were very heterogeneous, with dropout rates within the studies between 0 and 84%. A non-significant trend favoring CBZ was found in terms of dropouts (RR 0.88; 95% CI 0.75–1.03) and results from one trial suggest that fluoxetine patients are less likely to drop out. The main efficacy outcome reported in the studies was the presence of cocaine metabolites in the urine. No significant results were found, regardless the type of drug or dose used for all relevant outcomes assessed.
Conclusions There is no current evidence supporting the clinical use of CBZ, antidepressants, dopamine agonists, disulfiram, mazindol, phenytoin, nimodipine, lithium and NeuRecover-SA in the treatment of cocaine dependence. Larger randomized investigation must be considered, while taking into account that these time-consuming efforts should be reserved for medications showing more relevant and promising evidence. Given the high dropout rate among the test population, clinicians may wish to consider adding psychotherapeutic supportive measures aimed at keeping patients in treatment programs.